A Randomized, Double-blind, Placebo Controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics After Single and Multiple Administration of GV1001 in Healthy Subjects
Latest Information Update: 17 Oct 2024
At a glance
- Drugs Tertomotide (Primary)
- Indications Alzheimer's disease; Benign prostatic hyperplasia; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Progressive supranuclear palsy
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GemVax & KAEL
- 14 Oct 2024 Planned primary completion date changed from 30 Jun 2025 to 31 Aug 2025.
- 14 Oct 2024 Status changed from not yet recruiting to recruiting.
- 08 Oct 2024 New trial record